These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 370528)

  • 1. Pharmacology of ergot alkaloids in clinical use.
    Berde B
    Med J Aust; 1978 Nov; 2(3 Suppl):3-13. PubMed ID: 370528
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the central effects of ergot alkaloids by means of electroencephalography.
    Longo VG; Loizzo A
    Pharmacology; 1978; 16 Suppl 1():189-92. PubMed ID: 643900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine.
    Horowski R
    Adv Neurol; 1982; 33():325-34. PubMed ID: 7055013
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of prolactin secretion by ergot alkaloids.
    Nasr H; Pearson OH
    Acta Endocrinol (Copenh); 1975 Nov; 80(3):429-43. PubMed ID: 811032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour.
    Prysor-Jones RA; Jenkins JS
    J Endocrinol; 1980 Jul; 86(1):147-53. PubMed ID: 7430884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal damage induced by some ergot derivatives in vitro.
    Roberts G; Rand MJ
    Mutat Res; 1977 Apr; 48(2):205-14. PubMed ID: 876268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dopaminergic ergot combinations. A new therapeutic principle].
    von Werder K
    MMW Munch Med Wochenschr; 1983 Jun; 125(23):489-91. PubMed ID: 6410211
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep.
    Clarenbach P; Del Pozo E; Brownell J; Heredia E; Spiegel R; Cramer H
    Brain Res; 1980 Dec; 202(2):357-63. PubMed ID: 7437907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of ergot alkaloids on venous tonus determined in superficial hand veins in situ].
    Aellig WH
    Cardiology; 1976; 61 suppl 1():302-8. PubMed ID: 975144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ergot alkaloids and cyclic nucleotides in the CNS.
    Trabucchi M; Hofmann M; Montefusco O; Spano PF
    Pharmacology; 1978; 16 Suppl 1():150-55. PubMed ID: 205889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular effects of ergot alkaloids: a study on human basilar arteries.
    Müller-Schweinitzer E
    Gen Pharmacol; 1983; 14(1):95-102. PubMed ID: 6826043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 2-adrenergic agonist and alpha 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats.
    Roquebert J; Grenié B
    Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):30-7. PubMed ID: 2881518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology of ergotamine and dihydroergotamine.
    Silberstein SD
    Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dominant lethal effects of some ergot alkaloids.
    Roberts GT; Rand MJ
    Mutat Res; 1978 Jun; 50(3):317-25. PubMed ID: 672916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors.
    Villalón CM; De Vries P; Rabelo G; Centurión D; Sánchez-López A; Saxena P
    Br J Pharmacol; 1999 Feb; 126(3):585-94. PubMed ID: 10188968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the pharmacology of venous smooth muscle from dog and man.
    Müller-Schweinitzer E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):690-704. PubMed ID: 94863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1.
    Yamashita H; Kawakami H; Zhang YX; Tanaka K; Nakamura S
    J Neurol Sci; 1998 Feb; 155(1):31-6. PubMed ID: 9562319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of ergot alkaloids on sulfonylurea-stimulated insulin secretion in dogs.
    Sirek A; Sirek OV; Policova Z; Kerekes A
    Pharmacology; 1977; 15(3):259-67. PubMed ID: 405680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of dihydroergotoxine, bromocriptine, and ergotamine on penile erection in Wistar rats.
    Radosavljevic M; Pajovic B; Radunovic M; Radojevic N; Bjelogrlic B
    J Androl; 2012; 33(5):866-71. PubMed ID: 22441761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.